Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02472028
Other study ID # P100153
Secondary ID 2014 A00265-42
Status Recruiting
Phase Phase 4
First received
Last updated
Start date September 2015
Est. completion date September 11, 2028

Study information

Verified date May 2024
Source Assistance Publique - Hôpitaux de Paris
Contact Olivier HANON, MD, PhD
Phone 33 1 44 08 35 02
Email olivier.hanon@brc.aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to test the hypothesis of slowing the progression of White Matter Lesions (WML) by lowering blood pressure (BP) in patients with cognitive complaints and a moderate to high grade of WML on brain MRI.


Description:

SCIENTIFIC BACKGROUND: White Matter Lesions (WML) are cerebrovascular abnormalities discovered on MRI that are associated with an increased risk of dementia. High blood pressure (BP) is a major risk factor for WML. WML are therefore key lesions in the causal chain linking vascular factors and dementia, particularly Alzheimer's disease. However, it has not been shown that lowering BP could limit the progression of the WML in people with cognitive impairment. OBJECTIVES: To test the hypothesis of slowing progression of WML by lowering BP in patients with memory complaints with a moderate to high grade of WML on brain MRI. STUDY DESIGN: PROBE (Prospective randomized open blinded end-point) trial. Blind reading of both MRI for every patient in each group. After stratified randomization on age, sex and center, patients will be assigned to two strategies: - Reinforced Group (RG): enhanced strategy aiming at a systolic BP <135 mmHg; - Usual Group (UG): usual strategy based on the usual routine care. SAMPLE SIZE: patients will be enrolled (410 in each arm) in 12 Memory Resources and Research Center (CMRR) with access to 1.5 T or more MRI. CONDUCT OF THE STUDY: Duration of the inclusion period: 96 months and 2 weeks. Patient participation duration: 36 months + 6 months max Total study duration: 11 years. Clinical and para-clinical evaluation: MRI as part of research at the beginning of the study and before the end of the study at 36 months + 6 months max (primary endpoint); Clinical evaluation of neuropsychological tests at the beginning of the study and yearly ; walking speed measurement single leg stance balance test ; repeated BP measurements; monitoring of neurological signs and symptoms; blood test at the beginning of the study (electrolytes, lipid profiles, fasting blood glucose, if not existing); MRI if not existing for validation of the inclusion criterion and performed in the ordinary course.


Recruitment information / eligibility

Status Recruiting
Enrollment 820
Est. completion date September 11, 2028
Est. primary completion date September 11, 2028
Accepts healthy volunteers No
Gender All
Age group 60 Years to 88 Years
Eligibility Inclusion Criteria: - 60 to 88 years old patients; - Patient with cognitive complaint with MMSE = 20performed within 6 months prior to enrollment (with or without dementia) - Patient with a socio-educational level = 3 - Presence of hyperintensities of moderate to high grade on the last MRI or old scan (grades C and D on the modified Scheltens scale, grades 2/3 Fazekas). - Hypertension defined by a Systolic Blood Pressure (SBP) and / or a Diastolic Blood Pressure (DBP) = 140/90 mmHg, treated or not - Affiliation to a social security system - Informed consent given, signed consent Exclusion Criteria: - Presence of severe orthostatic hypotension defined as a decrease of 30 mmHg in SBP standing within 3 minutes - Contraindication to MRI (presence of ferromagnetic foreign body (especially some intracranial clips, some heart valves, intraocular foreign bodies, metal prosthesis), subject carrying pacemaker, claustrophobic participants) - Severe diseases associated with a life expectancy of less than 3 months; - Major physical impairments that can interfere with the feasibility of the tests (sight, hearing ...) - Presence of another dementia different than Alzheimer's disease vascular dementia or mixed dementia, - Persons under guardianship; - Secondary hypertension: renovascular hypertension, primary aldosteronism, pheochromocytoma ...; - Patient already receiving 4 or more antihypertensive drugs at maximum dosage - Patient participating in another clinical research study on drug requiring exclusion period - severe renal impairment

Study Design


Related Conditions & MeSH terms


Intervention

Other:
blood pressure lowering algorithm
The treatments used in the "enhanced strategy" arm are those proposed by national (HAS2013, SFHTA2013) and international (ESH 2013) recommendations, according to their Marketing Authorization and Summary of Product Characteristics : Diuretics, beta-blockers, Angiotensin Converting Enzyme inhibitors, Angiotensin Receptor Blockers, Calcium Channel Blockers Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. All drugs of these classes may be used , no specific drug is tested in this study.
usual strategy
The implementation of antihypertensive therapy the current recommendations to reach the blood pressure target in usual care. Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. Combinations of different pharmacological classes can be tested in order to find the most effective and best tolerated combinations.

Locations

Country Name City State
France Memory for Research and Resources Center / Neuroscience pole Bordeaux Pellegrin Hospital Group
France Memory Resources Centre and South of Ile de France Search - Broca Hospital Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary The main criterion is based on the quantitative assessment of White Matter Lesions (WML) volumes at the beginning and at the end of the study for each patient and each arm of the trial. The WML volume from the final MRI is compared to that of the initial 36 months + 6 months max
Secondary Imaging criteria : changes in the number of large or confluent WML 36 months+ 6 months max
Secondary Imaging criteria : changes in the volume of WML depending on their location (periventricular and deep white matter) 36 months+ 6 months max
Secondary Imaging criteria : changes in the number of silent infarctus 36 months+ 6 months max
Secondary Imaging criteria : changes in the number of microbleeds 36 months+ 6 months max
Secondary Imaging criteria : evolution of brain volumes (gray matter, white matter, CSF, and regional volumes including hippocampus) 36 months+ 6 months max
Secondary Clinical criteria: clinical criteria (changes in neuropsychological tests 36 months
Secondary Clinical criteria: changes inwalking speed 36 months
Secondary Clinical criteria: number of incident cases of dementia 36 months
Secondary Number of incident cases of vascular events validated by an expert committee 36 months
Secondary Clinical criteria: total mortality by cause 36 months+ 6 months max
See also
  Status Clinical Trial Phase
Completed NCT03239847 - Cost Effectiveness of the EndoPhys Pressure Sensing Access System vs. Radial A-line for Intra-operative Blood Pressure Monitoring N/A
Recruiting NCT03544801 - Renji Cerebral Small Vessel Disease Corhort Study
Recruiting NCT06010823 - Safety and Efficacy Evaluation of the Robotic Enhanced Error Training of Upper Limb Function in Post-stroke and Post TBI Participants N/A
Withdrawn NCT04991038 - Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients N/A
Completed NCT01915368 - Determining Optimal Post-Stroke Exercise (DOSE) N/A
Active, not recruiting NCT01555411 - Akershus Cardiac Examination (ACE) 1950 Study
Completed NCT01304576 - Orientation Agnosia: Clinical and Anatomical Study N/A
Completed NCT00049894 - Predictors of Recurrent Stroke in the PROGRESS Study N/A
Completed NCT00049920 - The ARIC MRI Study N/A
Completed NCT00059293 - Transcranial Doppler (TCD) Ultrasound of Subjects Enrolled in BABY HUG - Ancillary to BABY HUG
Completed NCT00005562 - Coronary Artery Calcium, Exercise Tests, and CHD Outcome N/A
Completed NCT00005395 - Honolulu Heart Program-Study of Stroke and Dementia N/A
Completed NCT00000479 - Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer Phase 3
Completed NCT00005140 - Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago N/A
Enrolling by invitation NCT00005485 - The Jackson Heart Study of Cardiovascular Disease Among African Americans
Recruiting NCT06275113 - BRING-UP Prevention
Completed NCT02702635 - Measuring Blood Flow Characteristics Using Dynamic Contrast Enhanced Magnetic Resonance Imaging N/A
Recruiting NCT04336852 - Development of a Clinically-relevant Test for Assessment of Cerebral Vascular Function N/A
Not yet recruiting NCT05892510 - Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke Phase 2/Phase 3
Completed NCT03994822 - pRESET for Occlusive Stroke Treatment N/A